<DOC>
	<DOCNO>NCT01971788</DOCNO>
	<brief_summary>Residual thrombosis stent strut may occur end primary angioplasty determine distal embolization myocardial damage . Bivalirudin consider appropriate antithrombotic drug set primary PCI , initial increase stent thrombosis report . In order overcome potential adverse event , prolonged infusion bivalirudin end PCI propose . This aim study test whether use long-term bivalirudin infusion , compare intra-procedural administration , reduce residual thrombosis stent strut evaluate optical coherence tomography ( OCT ) end primary PCI 3-5 day follow-up . A subgroup patient enrol MATRIX ( Minimizing Adverse haemmhorragic event TRansradial access site AngioX study ) study select show follow inclusion criterion : - patient affect STEMI undergoing primary PCI stent implantation randomise bivalirudin treatment , - patient , addition infarct related lesion , show least one critical stenosis coronary vessel suitable staged-PCI , - patient whose anatomy suitable OCT evaluation .</brief_summary>
	<brief_title>The MATRIX OCT Substudy</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<criteria>Patients enrol MATRIX ( Minimizing Adverse haemmhorragic event TRansradial access site AngioX study ) study show follow feature : 1. patient affected STEMI undergo primary PCI stent implantation randomise bivalirudin treatment , 2. patient , addition infarct related lesion , show least one critical stenosis coronary vessel suitable stagedPCI , 3. patient coronary anatomy suitable OCT evaluation . The criterion use MATRIX ( Minimizing Adverse haemmhorragic event TRansradial access site AngioX study ) study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>